24.07.2023 | ASO Author Reflections
ASO Author Reflections: Low Estrogen Receptor (ER) Expression Breast Cancer Behaves More like ER Negative Disease and Influences Management
verfasst von:
Dan Moldoveanu, MD, MCh, Matthew P. Goetz, MD, Judy C. Boughey, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 11/2023
Einloggen, um Zugang zu erhalten
Excerpt
The value of hormone receptor expression is well established in the treatment and prognosis of breast cancer. Positivity thresholds have been selected on the basis of previous endocrine therapy studies, in which patients with breast cancer with at least 1% estrogen receptor (ER) and/or progesterone receptor (PR) expression were found to derive benefit from these therapies.
1 However, breast cancers exist on a continuum of hormone receptor positivity, and while a dichotomous classification (positive versus negative) serves well to inform endocrine therapy use, this approach fails to capture nuances in disease biology. More recently, the AJCC 8th edition added hormone receptor status as an integral part of breast cancer staging, highlighting its important prognostic role.
2 …